Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 7:46 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2257–2280 of 13,632 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Dermatologic Disorders Clear all

Conditions: Dermatitis, Atopic
Interventions: GSK1070806, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 8
States / cities: North Little Rock, Arkansas • Miami, Florida • Tampa, Florida + 5 more

Conditions: Metastatic Breast Cancer
Interventions: Patients and Caregivers Qualitative Interview; Behavioral
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Acne Vulgaris, Scar
Interventions: Microneedling, Fractional non-ablative 1,540nm laser; Device
Lead sponsor: Boston University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Melanoma, Renal Cell Carcinoma, Sarcoma, Breast Cancer, Lung Cancer, Colorectal Cancer, Gastrointestinal Cancers, Brain Metastases
Interventions: Gamma Knife Radiosurgery; Procedure
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Blastic Plasmacytoid Dendritic Cell Neoplasm
Interventions: Venetoclax; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 2
States / cities: Boston, Massachusetts • Houston, Texas

Conditions: Hidradenitis Suppurativa (HS)
Interventions: Upadacitinib, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 18
States / cities: Phoenix, Arizona • Little Rock, Arkansas • San Diego, California + 15 more

Conditions: Metastatic Breast Cancer
Interventions: ixabepilone; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Solid Tumor, Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung
Interventions: ATI-1123 (active drug = docetaxel); Drug
Lead sponsor: Azaya Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 2
States / cities: Dallas, Texas • San Antonio, Texas

Conditions: Cellulitis, Skin and Subcutaneous Tissue Infection
Interventions: Thermal Imaging as Diagnostic Adjunct; Diagnostic Test
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 416 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Psoriasis
Interventions: MEDI-522, Placebo; Drug · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 18
States / cities: Little Rock, Arkansas • Fresno, California • Vallejo, California + 15 more

Conditions: Breast Cancer
Interventions: Breast Magnetic Resonance Imaging (MRI), Contrast Enhanced Mammography (CEDM); Diagnostic Test
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Female only
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 5
States / cities: Basking Ridge, New Jersey • Montvale, New Jersey • Commack, New York + 2 more

Conditions: Healthy Volunteers, Breast Cancer, Metastatic
Interventions: Blood draw; Diagnostic Test
Lead sponsor: Angle plc; Industry
Eligibility: 22 Years and older · Female only
Enrollment: 421 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 4
States / cities: Los Angeles, California • Chicago, Illinois • Rochester, New York + 1 more

Conditions: Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer
Interventions: BBI-940, Fulvestrant; Drug
Lead sponsor: Boundless Bio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 8
States / cities: Los Angeles, California • Lake Success, New York • Austin, Texas + 4 more

Conditions: Breast Cancer, Cardiotoxicity, Drug-Related Side Effects and Adverse Reactions, Cardiovascular Diseases
Interventions: Social Determinants of Health; Other
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2039
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Melanoma (Skin)
Interventions: dasatinib; Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2020
U.S. locations: 153
States / cities: Little Rock, Arkansas • Stanford, California • Fort Lauderdale, Florida + 106 more

Conditions: Cancer of the Breast, Anomaly of Breast
Interventions: Autologous Fat Grafting of the Breast, Control Arm; Procedure · Other
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years and older · Female only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Clackamas, Oregon

Conditions: Secondarily Infected Traumatic Lesions (SITL), Impetigo
Interventions: 2% TD1414 Cream; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: College Station, Texas

Conditions: Metastatic Invasive Breast Cancer, Resistant Breast Cancer, ER+, HER2-, Metastatic Breast Cancer
Interventions: Neratinib + endocrine therapy, Endocrine therapy may include one of the following therapies: letrozole, anastrozole, exemestane, tamoxifen or fulvestrant, CDK4/6 + Endocrine therapy; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older · Female only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2035
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Breast Cancer
Interventions: Endocrine Therapy and a CDK 4/6 inhibitor; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 100 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Breast Cancer
Interventions: Gemcitabine, Trastuzumab, Cisplatin; Drug
Lead sponsor: Kari Kendra; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Granulomatosis With Polyangiitis (Wegener's), Granulomatosis With Polyangiitis, Wegener's Granulomatosis, ANCA-Associated Vasculitis
Interventions: Abatacept, placebo; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 15 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 10
States / cities: Los Angeles, California • Tampa, Florida • Kansas City, Kansas + 7 more

Conditions: Breast Cancer Female, Leptomeningeal Metastases
Interventions: HER2 BATs; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Carcinoma, Sarcoma, Myeloma, Lymphoma, Melanoma
Interventions: [18F]-SKI-249380, PET/CT scan, Blood draws; Radiation · Procedure · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 21 Years to 90 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Male Breast Cancer, Recurrent Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions: mifepristone, placebo, nab-paclitaxel; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 2
States / cities: Chicago, Illinois • Evanston, Illinois

Search by objective public record fields.

Clinical Effect, Safety and Tolerability of GSK1070806 in Atopic Dermatitis

Metastatic Breast Cancer-Specific Prognostic Tool

Acne Scarring in Skin of Color: Laser vs Microneedling

A Pilot/Phase II Study of Gamma Knife Radiosurgery for Brain Metastases Using 3Tesla MRI and Rational Dose Selection

Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease Symptoms

Phase II Study of Ixabepilone in Metastatic Breast Cancer and Its Effects on the Ultrastructure of Neurons

Safety Study of a Liposomal Docetaxel Formulation in Patients With Solid Tumors Who Have Failed Previous Therapies

Utility of Thermal Imaging in Diagnosis of Cellulitis for Lower Extremity Complaints in the Emergency Department

Study of MEDI-522 Administered by Subcutaneous Injection to Adults With Plaque Psoriasis

Comparison of MRI and CEDM to Evaluate Treatment Response Before Surgery

Harvest of CTCs From MBC Patients Using the Parsortix™ PC1 System

Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer

Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Breast Cancer

Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery

Autologous Fat Grafting of the Breast in Women With Post Lumpectomy Contour Defects

The Pharmacokinetics of 2% TD1414 Cream in Adults With Secondarily Infected Traumatic Lesions (SITL) or Impetigo

Neu Direction: Testing the Efficacy of Adding HER Inhibition to Standard of Care in Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast Cancer

Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC

Gemcitabine/ Trastuzumab and Gemcitabine/ Cisplatin/ Trastuzumab in Patients With Metastatic Breast Cancer

Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's)

BATs in Patients With Breast Cancer and Leptomeningeal Metastases

PET Imaging of Cancer Patients Using [18F]-SKI-249380, a Radiolabeled Dasatinib-Derivative

Nab-paclitaxel (Abraxane) With or Without Mifepristone in Patients With Advanced Breast Cancer